Physician profile
Thomas H Patton
NPI 1790832582
$20,307.86
in general payments reported to CMS, 2019-2025
75 companies · $3,877 in 2025
The $3,877 reported for 2025 was more than what 82% of Neurology (Psychiatry & Neurology) providers received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,712 · 2020: $1,846 · 2021: $2,745 · 2022: $3,028 · 2023: $3,018 · 2024: $4,082 · 2025: $3,877.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $11K.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $10,976.68 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,443.82 | 2021-2025 | |
| Pfizer INC. | $1,192.71 | 2019-2025 | |
| Biogen, INC. | $1,091.24 | 2019-2025 | Vumerity, Tysabri, Avonex |
| Csl Behring | $1,070.00 | 2020-2025 | Hizentra |
| Novartis Pharmaceuticals Corporation | $991.43 | 2019-2025 | |
| Neurocrine Biosciences, INC. | $691.99 | 2019-2025 | Ingrezza, Ongentys |
| Amgen INC. | $593.77 | 2019-2025 | Uplizna |
| Ucb, INC. | $560.69 | 2019-2025 | Rystiggo, Fintepla, Zilbrysq |
| Genentech USA, INC. | $550.92 | 2019-2025 | Ocrevus, Ocrevus Zunovo |
| Teva Pharmaceuticals USA, INC. | $515.48 | 2019-2023 | Austedo Xr |
| Eisai INC. | $512.01 | 2019-2025 | |
| Alexion Pharmaceuticals, INC. | $445.45 | 2019-2025 | Ultomiris |
| Lilly USA, LLC | $437.48 | 2019-2025 | Amyvid, Emgality, Kisunla |
| Acadia Pharmaceuticals INC | $422.37 | 2019-2025 | Nuplazid |
| Sk Life Science, INC. | $422.36 | 2020-2025 |
Show all 75 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thomas Patton listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.